PharmAla Biotech Logo 800 x 422.png
PharmAla to supply Mt. Sinai Hospital with LaNeo MDMA
October 21, 2024 09:25 ET | PharmAla Biotech
PharmAla contracted to sell MDMA to Mt. Sinai Hospital, NY. Terminates Contract with CCrest Labs.
PharmAla Biotech Logo 800 x 422.png
PharmAla to supply the University of Texas, San Antonio, with novel dosage form of LaNeo™ MDMA
October 08, 2024 08:55 ET | PharmAla Biotech
PharmAla signs contract to develop novel dosage form of LaNeo MDMA, to be used in clinical trial at University of Texas San Antonio
PharmAla Biotech Logo 800 x 422.png
PharmAla to supply Harvard Medical School’s Maclean Hospital with LaNeo MDMA
October 02, 2024 09:20 ET | PharmAla Biotech
PharmAla Biotech signs contract to supply Harvard neuropsychiatry hospital with MDMA; Appears at CPHI Conference in Milan
PharmAla Biotech Logo 800 x 422.png
PharmAla to supply Johns Hopkins Medicine for Clinical Trial
September 11, 2024 08:55 ET | PharmAla Biotech
PharmAla completes sales agreement with Johns Hopkins Medicine, terminates contract with Red Light Holland, to present novel molecule at conference.
MAPS-Logo-2021-Primary-Horizontal-White-Background-1200x486.jpg
MAPS Awards Grant for Pilot MDMA-assisted Massed Exposure Therapy Trial MAPS, which has incubated and funded cutting-edge psychedelic research for decades, is continuing to advance our understanding of psychedelic-assisted therapiesThis study is one of the first trials...
PharmAla Biotech Logo 800 x 422.png
PharmAla Launches MDMA Clinical Trial Tool for Researchers
August 22, 2024 09:07 ET | PharmAla Biotech
PharmAla announces the launching of a new tool for clinical researchers, and the appointment of a new CFO effective Oct. 1
MAPS-Logo-2021-Primary-Horizontal-White-Background-1200x486.jpg
MAPS Statement on FDA Complete Response Letter for MDMA-Assisted Therapy for PTSD New Drug Application MAPS remains confident in its goal of making access to MDMA-assisted therapy for PTSD safe and legal SAN JOSE, Calif., Aug. 09, 2024 (GLOBE NEWSWIRE) -- The Multidisciplinary Association for...
psycanlogo.png
PsyCan Comments on FDA Decision Re: Lykos MDMA-Assisted Therapy Application
August 09, 2024 18:28 ET | Psychedelics Canada
Psycan comments on USFDA's recent decision to request a third phase 3 trial prior to approval of
PharmAla Biotech Logo 800 x 422.png
PharmAla Comments on USFDA Decision regarding MDMA-Assisted Therapy and Announces Patent Granting for ALA-002
August 09, 2024 18:18 ET | PharmAla Biotech
PharmAla expresses disappointment in USFDA's decision to request a third Phase 3 for MDMA and announces the patent granting for a safer MDMA analog variant
PharmAla Biotech Logo 800 x 422.png
PharmAla Provides Comprehensive Investor Update Following Release of Q3 Financial Statement
July 30, 2024 08:55 ET | PharmAla Biotech
PharmAla releases a comprehensive investor update following its Q3 financial release, including highlights such as a 10x revenue increase and patent update